18
total announcements
CONCORDBIO.NS · 15 min delayed
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting to be held on August 26, 2026, in Ahmedabad.
Concord Biotech Limited
Concord Biotech Limited has reported a strong start to FY27 with Q1 FY27 revenues of INR257 crores, reflecting a 26% year-on-year growth. The company has overcome challenges in FY26 and is confident of sustaining this momentum over the coming quarters.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about the link to the recording of their earnings call for the first quarter ended June 30, 2026.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about Presentation of unaudited Standalone and Consolidated Financial Results for the first Quarter ended on June 30, 2026. The company witnessed broad-based growth across all product categories, with exports growing by ~46% for Q1FY27 (Y-o-Y). The company received USFDA approval for its ANDA for Mycophenolate Mofetil & Tofacitinib Tablets and started commercial operations & sales at Stellon Biotech. The company also received a Silver medal from EcoVadis placing Concord among the top 15% companies assessed globally.
Concord Biotech Limited
Concord Biotech Limited has submitted the voting results and Scrutinizer's Report of the 41st Annual General Meeting held on July 31, 2026. All resolutions were passed with requisite majority.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about the unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026, which have been published in the Financial Express newspaper and uploaded on the company's website.
Concord Biotech Limited
Concord Biotech Limited held its 41st Annual General Meeting on July 31, 2026, through video conferencing. The meeting was attended by 38 members, and the requisite quorum was present. The Chairman and Managing Director, Mr. Sudhir Vaid, addressed the shareholders and gave an overview of the company's operations and financial performance for the year ended March 31, 2026. The meeting concluded with the approval of the Notice convening the 41st Annual General Meeting and the Directors' Report, which had already been circulated to the members.
Concord Biotech Limited
Concord Biotech Limited has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with the Board of Directors approving the results after reviewing and recommending them from the Audit Committee.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about Schedule of meet to discuss the unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about a copy of newspaper publication for the 41st Annual General Meeting, notice of candidature for the office of Director, record date, and the availability of the e-voting facility.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 24-Jul-2026. The 41st Annual General Meeting (AGM) of the Company will be held on Friday, July 31, 2026, through Video Conferencing / Other Audio Visual Means. The Register of Members and Share Transfer Books of the Company will be closed from Saturday, July 25, 2026 to Friday, July 31, 2026.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 31, 2026.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange about a copy of newspaper publication regarding notice of 41st Annual General Meeting and related matters.
Concord Biotech Limited
Concord Biotech Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of securities on stock exchanges.
Concord Biotech Limited
Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Concord Biotech Limited
Concord Biotech Limited has completed the inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at its Unit-II formulation facility.
CONCORDBIO
Concord Biotech Limited (CONCORDBIO) has announced an investment agreement with FSGE Renewable Power Private Limited, categorised under an acquisition intimation. The company will invest in a Wind Solar Hybrid Power Project designed with a wind capacity of approximately 6.3 MW AC. This strategic move, which follows a previous intimation, marks CONCORDBIO's entry into renewable energy generation. For investors, this signifies the company's commitment to sustainable practices and could lead to long-term operational efficiencies.
Concord Biotech Limited
Concord Biotech Limited has informed the exchanges about its upcoming schedule for an Analyst/Institutional Investor meet. The company's officials will participate in a Non-Deal Roadshow (NDR) to engage with investors. This outreach allows the company to interact directly with the investment community, sharing insights into its operations and strategy. While no specific financial figures or immediate decisions were disclosed, such events help foster transparency and investor relations.